Medicaid Coverage Rules and Real-World Challenges in Getting Tirzepatide

A 34-year-old woman faced six months of treatment delays for tirzepatide due to restrictive Ohio Medicaid policies.

• Medicaid beneficiaries often encounter barriers to accessing approved metabolic therapies.
• Tirzepatide is FDA-approved for type 2 diabetes, obstructive sleep apnea, and obesity.
• State Medicaid programs sometimes impose diagnosis-based restrictions that conflict with FDA labeling.
• Diagnostic silos and inconsistent authorization processes can delay treatment for patients who meet FDA criteria.
• Variation in coverage across Medicaid programs may limit access to glucagon-like peptide-1 (GLP-1) therapies.
• Aligning Medicaid coverage with FDA indications could promote more equitable healthcare access.

Simplified